

RECEIVE

APR 18 2001

TECH CENTER 1600/2

wherein said active ingredient comprises or expresses at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof,

wherein said antigen is an immunologically reactive portion of human prostate-specific antigen (PSA); or

human prostate-specific membrane antigen (PSMA) or an immunologically effective portion thereof; or

human prostate-specific membrane antigen (PSMA) or an immunologically effective portion thereof; or

prostatic acid phosphatase (PAP) or an immunologically reactive portion thereof; or mixtures of the foregoing; or

wherein said active ingredient comprises a nucleic acid that generates said antigen or antigens *in situ*.